FLT3 ITD/TKD Mutation Analysis
Alternative name:
FLT3, FLT3 TKD, FLT3 ITD
Methodology
Molecular
Test Description and clinical significance
Genes
FLT3 ITD/TKD
Disease:
Cytogenetically normal Acute Myeloid Leukemia & Acute Lymphoblastic Leukemia, colon adenocarcinoma, lung adenocarcinoma, cutaneous melanoma, and breast invasive ductal carcinoma
Next generation sequencing of gene panel. FLT gene encodes a class III receptor tyrosine kinase that regulates hematopoiesis. This receptor is activated by binding of the fms-related tyrosine kinase 3 ligand to the extracellular domain, which induces homodimer formation in the plasma membrane leading to autophosphorylation of the receptor. The activated receptor kinase subsequently phosphorylates and activates multiple cytoplasmic effector molecules in pathways involved in apoptosis, proliferation, and differentiation of hematopoietic cells in bone marrow. Two types of FLT3 gene mutations are possible. FLT3 internal tandem duplication (FLT3-ITD), FLT3-TKD mutations (tyrosine kinase domain).
NGS-AML Panel is recommended.
Specimen Requirements
Collection:
At least 0.5 ml EDTA, citrate (ACD) or Heparinized whole blood or bone marrow aspirates for DNA mutations
Stability:
96hours/4 to 7 days refrigerated
Unacceptable Conditions:
Specimen submitted is in the incorrect fixative or anticoagulant. Specimen received after the stability date. Gross hemolysis. Frozen specimen. Insufficient specimen. Unlabeled. Left un-refrigerated for an extended period.
Storage & Transport
Blood, bone marrow specimens should be kept at room temperature and preferably received within 96 hrs of drawing. Samples that are 4 to 7 days old should be refrigerated.
CPT(s)
81245 for ITD & 81246 for TKD
New York Approved
NO
TAT
10 Days
*The CPT codes provided are for informational purposes only and are based on AMA guidelines The billing party is solely responsible for correct CPT coding.
